Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection

Infection and Immunity

Volumn 69, Issue 6, 2001, Pages 3581-3590

  Kotloff, K L ^a   Sztein, M B ^a   Wasserman, S S ^a   Losonsky, G A ^a   DiLorenzo, S C ^a   Walker, R I ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; BACTERIAL TOXIN; FORMALDEHYDE; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; INACTIVATED VACCINE; PLACEBO; VACCINE;

ADULT; ARTICLE; ATROPHIC GASTRITIS; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ESCHERICHIA COLI; FEMALE; FEVER; HELICOBACTER PYLORI; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; NORMAL HUMAN; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; STOMACH MUCOSA; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL TOXINS; BACTERIAL VACCINES; DOUBLE-BLIND METHOD; ENTEROTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNITY, MUCOSAL; INTERFERON TYPE II; INTERLEUKIN-5; LYMPHOCYTE ACTIVATION; MIDDLE AGED; VACCINATION; VACCINES, ATTENUATED;

EID: 0035010023     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.69.6.3581-3590.2001     Document Type: Article

References (68)

1. Pilot study of phoPlphoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers
2. Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype
3. High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: Relation with previous nitroimidazole exposure and gastroduodenal disease
4. Urease-specific monoclonal antibodies prevent Helicobacter felis infection in mice
5. Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures
6. Helicobacter pylori and gastric carcinoma. Serum antibody prevalence in populations with contrasting cancer risks
7. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice
8. Serum neutralizing antibody response to the vacuolating cytotoxin of Helicobacter pylori
9. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology
10. What is the role for vaccination in Helicobacter pylori?
11. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization
12. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity
13. Urease-based mucosal immunization against Helicobacter heilmannii infection induces corpus atrophy in mice
14. Safety and immunogenicity of phoPlphoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers
15. Therapeutic immunisation against Helicobacter infection
16. Helicobacter pylori in the pediatric patient
17. Vaccination of gnotobiotic piglets against Helicobacter pylori
18. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses
19. Gastric T lymphocyte responses to Helicobacter pylori in patients with H. pylori colonisation
20. Recombinant antigens prepared from the urease subunits of Helicobacter spp.: Evidence of protection in a mouse model of gastric infection
21. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice
22. High incidence of Campylobacter-like organisms in endoscopic biopsies from patients with gastritis, with or without peptic ulcer
23. Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation
24. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection
25. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study
26. Role of trypsin-like cleavage at arginine 192 in the enzymatic and cytotonic activities of Escherichia coli heat-labile enterotoxin
27. Enterotoxic effect of the vacuolating toxin produced by Helicobacter pylori in Caco-2 cells
28. The association of Helicobacter pylori with gastric cancer and preneoplastic gastric lesions in Chiapas, Mexico
29. Systemic immunization with urease protects mice against Helicobacter pylori infection
30. Differential stimulation of interleukin-12 (IL-12) and IL-10 by live and killed Helicobacter pylori in vitro and association of IL-12 production with gamma interferon-producing T cells in the human gastric mucosa
31. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: Randomised controlled trial
32. Therapeutic oral vaccination induces mucosal immune response sufficient to eliminate long-term Helicobacter pylori infection
33. Interferon gamma and interleukin 4 secreting cells in the gastric antrum in Helicobacter pylori positive and negative gastritis
34. Immune response to an 18-kilodalton outer membrane antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine candidate
35. Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection
36. The epidemiology of Helicobacter pylori in Peruvian children between 6 and 30 months of age
37. Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine
38. Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori
39. Pseudomonas aeruginosa and Pseudomonas cepacia isolated from cystic fibrosis patients bind specifically to gangliotetraosylceramide (asialo GM1) and gangliotriaosylceramide (asialo GM2)
40. Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence Ga1NAc beta 1-4Gal found in some glycolipids
41. Prevalence/disease correlates of H. pylori
42. Successful immunization against gastric infection with Helicobacter species: Use of a cholera toxin B-subunit-whole-cell vaccine
43. Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys
44. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis
45. Development of a mouse model of Helicobacter pylori infection that mimics human disease
46. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant
47. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori
48. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease
49. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults
50. NIH Consensus Conference: Helicobacter pylori in peptic ulcer disease
51. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii
52. Helicobacter pylori infection and the risk of gastric carcinoma
53. Attenuated ΔguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses
54. Catalase, a novel antigen for Helicobacter pylori vaccination
55. Cure of duodenal ulcer associated with eradication of Helicobacter pylori
56. Low rates of Helicobacter pylori reinfection in children
57. Helicobacter pylori vaccine development and use: A cost-effectiveness analysis using the Institute of Medicine methodology
58. Immunization of BALB/c mice with Helicobacter urease B induces a T helper 2 response absent in Helicobacter Infection
59. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor
60. Helicobacter pylori reinfection with identical organisms: Transmission by the patients' spouses
61. Cytokine production patterns and lymphoproliferatlve responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi
62. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato
63. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin
64. Suppressive effects of DNA vaccines encoding heat shock protein on Helicobacter pylori-induced gastritis in mice
65. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori
66. Salmonella typhi flagella are potent inducers of proinflammatory cytokine secretion by human monocytes
67. Recurrence of Helicobacter pylori infection after successful eradication: Nature and possible causes
68. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity